Full Breakdown
Oura Delays Nasdaq Debut Amid Market Uncertainty
By Drooid · · How we work
Core Event
On September 29, Oura Health announced that it is postponing its planned initial public offering on the Nasdaq. The company cited “uncertainty in the IPO market” despite reporting “strong demand” from investors. The offering, announced in an S-1 filing earlier, would have sold 50 million shares at $40-$44 each, targeting up to $2.2 billion in proceeds and a fully diluted valuation of about $15.62 billion.
Background & Context
Oura, founded in 2013 in Finland and headquartered in San Francisco, CA, has built a niche in health-focused wearables with its Oura Ring. The device tracks sleep, heart-rate variability, activity and body temperature, positioning itself between traditional fitness trackers and smartwatches. The company went public in its home market in 2020 and has since expanded its subscription-based health platform. Earlier in 2026, several technology firms—including nuclear-services firm Holtec and insurance startup Bamboo—also postponed IPOs, reflecting broader volatility in the U.S. equity market.
Data & Statistics
- Revenue: $1.4 billion for the 12 months ended June 30 2026.
- Revenue growth: Projected 90 % year-over-year increase for fiscal 2026.
- Paid members: 5.7 million, up from 5 million at the end of June.
- Profitability: Net income rose from $1.6 million to $60.8 million in the nine months ended June 30.
- Offering size: 13.5 million primary shares plus 36.5 million secondary shares, priced $40-$44 each.
- Investor interest: Institutional investors Eli Lilly and Dragoneer Investment Group indicated intent to purchase up to $100 million and $300 million, respectively.
Official Statements & Responses
He added that Oura will continue to “execute against the opportunities ahead.”
Analysts observed that higher interest rates are prompting investors to be more selective on growth-oriented valuations, though some, such as Anthropic’s upcoming IPO, suggest the market is not closed.
Conflicting Reports & Gaps
- Oversubscription level: Reuters quoted Muehlbauer describing the demand as “around four times oversubscribed,” while other outlets simply reported “strong demand” without quantifying the oversubscription.
- Valuation target: The filing listed a valuation of $15.62 billion, yet some commentary referenced a “valuation north of $2 billion,” creating ambiguity about the company’s internal expectations versus market perception.
No public timeline has been provided for a rescheduled IPO, and Oura has not disclosed whether the postponement will affect its secondary-share sellers.
Why It Matters
The delay underscores the heightened caution among high-growth consumer-tech firms facing a market environment marked by rising interest rates, geopolitical tensions and investor skepticism toward hardware-centric business models. Oura’s decision may influence other wearable and health-tech companies that are weighing the trade-off between private funding and public-market valuations.
What's Next
Oura indicated that it will remain privately held while monitoring market conditions. The company’s existing investors appear prepared to supply additional capital, allowing Oura to continue product development and subscription growth without immediate pressure to price its shares in a volatile market.